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Abstract
Background: The aim was to investigate CD4+T-cell subsets, immune cells and their cytokine profiles in blood and
synovial compartments in rheumatoid arthritis (RA) and inflammatory osteoarthritis (OA) to define specific immune
signatures.
Methods: Peripheral blood, synovial fluid (SF) and synovial membranes (SM) of RA and OA patients were analyzed.
CD4+T-cell subset frequencies were determined by flow cytometry, and cytokine concentrations in serum and SF
were measured by ELISA.
Results: In peripheral blood, OA patients had altered frequencies of regulatory T-cell subsets, and higher frequencies of
Th17 and of Th1/17 cells than RA patients. In the synovial compartment of OA patients, conventional Th17 cells were
largely excluded, while Th1/17 cells were enriched and more frequent than in RA patients. Conversely, in the synovial
compartment of RA patients, regulatory T cells and Tfh cells were enriched and more frequent then in OA patients.
IL-17 and Blys were increased both in serum and SF of RA patients, and correlated with autoantibodies and disease
activity. Notably, Blys levels were already significantly elevated in RA patients with low disease activity score in 28 joints
(DAS28) and without autoantibody positivity.
Conclusions: Although patients with inflammatory OA have immune activation in the synovial compartment, they
display different T-cell subset frequencies and cytokine profiles. Soluble mediators such as Blys might help to
discriminate mild clinical forms of RA from inflammatory OA particularly at the onset of the disease.
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Background
Rheumatoid arthritis (RA) and osteoarthritis (OA) rep-
resent two manifestations of inflammatory arthritides.
Although the etiopathology of these diseases is differ-
ent, they both involve synovial inflammation [1]. While
RA is an autoimmune disease characterized by chronic
relapsing-remitting inflammation of the peripheral
joints [2], OA is induced by multifactorial mechanisms
established primarily by biomechanical stress [3]. Thus,
for a long time it has been believed that only patients
with RA may have immune cells in the synovial infiltrate.
However, recent reports showed that patients with OA also
have inflammatory synovial infiltrates that, particularly in
the most severe forms, are characterized by high-grade in-
flammation and could lead to abrupt onset, marked clinical
symptoms and structural damage [4]. Those patients with
inflammatory OA have inflammatory features that in some
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instances resemble those of RA. CD4+T-cells are key to the
initiation and progression of synovitis [2, 5] in patients with
RA, and cytokines released into the synovial fluid (SF) by
the inflamed tissue likely reflect the composition of effector
and regulatory T cells infiltrating the synovia [6]. Relatively
little is known about the characteristics of synovial im-
mune cells in patients with inflammatory OA, although
recent studies suggest that CD4 + T cells might contribute
to the pathophysiology of OA and correlated symptoms,
such as pain [7, 8].
Here, we further evaluated the role of CD4+ T cells by
in-depth analysis of subset composition and the cytokine
milieu in peripheral blood and SF during effusion epi-
sodes in patients with RA and OA, and of the synovial
membrane in patients who also underwent joint biopsy
or surgery. We tested correlation between the disease
activity parameters and the immunologic alterations in
order to determine whether different synovial profiles of
immune cells or cytokines could be specifically associated
with different types of arthropathy. We report that patients
with inflammatory OA display synovial immune activation
that presents different signatures in comparison to RA.
Methods
Human samples and patients
Buffy-coat blood from 25 healthy age-matched and sex-
matched donors (mean age 42 years; age range 26–58
years; male/female ratio 10/15) were obtained from the
IRCCS Policlinico Ospedale Maggiore, Milan, Italy. There
were 25 patients with RA (mean age 56 years; age range
40–72 years; male/female ratio 12/13) and 18 patients
with inflammatory OA (mean age 69 years; age range
57–86 years; male/female ratio 8/10), who were attending
the Rheumatology Department of the ASST-Gaetano Pini/
CTO Orthopedic and Traumatology Specialist Center of
Milan, enrolled in this study. All patients with RA fulfilled
the European League Against Rheumatism/American Col-
lege of Rheumatologists (EULAR/ACR) 2010 classification
criteria and their disease activity were assessed using the
disease activity score in 28 joints (DAS28) based on the
erythrocyte sedimentation rate (ESR) [9]. The median dur-
ation of RA was 4.3 ± 3.9 years. We included symptomatic
patients with radiographic evidence of mild knee OA
(Kellgren and Lawrence grade 2) with an active inflam-
matory phenotype characterized by the presence of
knee effusion synovitis and synovial thickening detected
by ultrasound (US) [10]. Clinical, biochemical and cel-
lular data on the enrolled patients with RA and OA are
summarized in Table 1.
Peripheral blood (PB) was obtained and collected in
heparinized tubes. SF samples from the knee joints of
patients with RA and OA were collected during therapeutic
needle aspiration into heparinized tubes. SM samples were
taken from two patients with RA who also underwent knee
Table 1 Summary of clinical, biochemical and cellular data on patients with RA and OA
Characteristic Rheumatoid arthritis Osteoarthritis
PBa SFb SMc PBa SFb SMc
Number 25 9 4 11 10 9
RF (n)d 17 9 4
ACPA (n)e 17 9 4 - - -
DAS28f index, low (0–3) mean 2.42 10/25 0/9 3/4 - - -
DAS28f index, medium (3–5)
mean 4.26
12/25 6/9 1/4 - - -
DAS28f index, high (>5)
mean 5.55
3/25 3/9 0/4 - - -
ESRg (mm/h) 56.3 (5–87) 10.3 (1–25)
CRPh (mg/dl) 4.3 (0.4–7.5) 0.27 (0–0.6)
NSAIDi (+/−) 8/25 14/18
Corticosteroids (+/−) 14/25 0/18
DMARDsj (+/−) 25/25 0/18
PBMCsk (106/ml) 1.8 (1.4–2.3) 1.6 (1.3–1.9)
SFMCsl 6.2 (3.6–11.3) *105/ml 9.2 (4.6–18.2) *104/ml
SMMCsm 3.2 *106 1.3 *106
aPB peripheral blood, bSF synovial fluid, cSM synovial membrane, dRF rheumatoid factor, eACPA anti-citrullinated protein antibody, fDAS28 disease activity score
based on 28 joint counts, gESR erythrocyte sedimentation rate, hCRP C-reactive protein (CRP), iNSAIDs non-steroidal anti-inflammatory drugs, jDMARDs disease-
modifying anti-rheumatic drugs, kPBMCs peripheral blood mononuclear cells, lSFMCs synovial fluid mononuclear cells, mSMMCs synovial membrane mononuclear
cells. *Mean, (values range). dRF nephelometry assay, cutoff value >15 UI/ml. All patients with RA had high positive dRF levels (more than three times the ULN for
the laboratory and assay): 264 ± 190. eACPA: QUANTA Lite® CCP3.1 IgG/IgA ELISA (INOVA Diagnostics), cutoff value >20 UI/ml. All patients with RA had high posi-
tive eACPA levels (more than three times the ULN for the laboratory and assay):125 ± 64. hCRP cutoff value 1 mg/dl.
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joint biopsy and from nine patients with OA and two
patients with RA who additionally had knee replacement
surgery.
The majority of patients with RA had medium/low
disease activity (as summarized in Table 1), and were on
medium/low doses of disease modifying anti-rheumatic
drugs (DMARDs) (hydroxychloroquine, methotrexate or
leflunomide). Thirteen out of twenty-four patients were
on low-dose corticosteroid therapy (<8 mg/day). No
patient was treated with biological therapy. See Table 1
for details.
Cell isolation
PB, SF and SM were collected. Peripheral blood mono-
nuclear cells (PBMCs) and synovial fluid mononuclear
cells (SFMCs) were directly isolated by Ficoll-Hypaque
gradient (Sigma-Aldrich). Synovial membrane mono-
nuclear cells (SMMCs) were isolated by Ficoll-Hypaque
gradient (Sigma-Aldrich) after digestion of the tissue
with Collagenase Type II (1 ml solution per 40 mg tis-
sue; Sigma-Aldrich) for a variable length of time ranging
from 1 h up to 6 h according to the size of the tissue
sample.
Flow cytometry
Single-cell suspension of cells was stained with the fol-
lowing antibodies: CD3 (UCHT1), CD4 (RPA-T4; VIT4),
CD8 (RPA-T8; OKT8), CD19 (HIB19), CD56 (B159,),
CD127 (eBioRDR5), CD25 (M-A251 BD; BC96), ICOS
(ISA-3), CXCR5 (51505), CCR6 (11A9) and CCR5 (27D/
CCR5), obtained from BD Bioscience (Becton, Dickinson
and Company, NJ, USA), eBioscience (eBioscience Inc,
CA, USA), Miltenyi (Miltenyi Biotec GmbH, DE) or R&D
(R&D Systems, MN, USA). Samples were passed on a
FACSCanto flow cytometer. CD4+ T-cell subsets were
gated according to well-established phenotypic markers
[11]. Thus, Tfh-cells were gated as CD4+CXCR5+ICOS+
[12], Th1 cells as CD4+CD127hiCD25−CXCR3+CCR6−,
Th17 cells as CD4+CD127hiCD25−CXCR3−CCR6+ [13]
and Th1/17-cells as CD4+CD127hiCD25−CXCR3+CCR6+
[14]. T regulatory cells (Tregs) were gated as CD4
+CD127loCD25+ and Tr1 cells as CD4+CD127−CD25
−CCR5+CCR6− [15]. Data were analyzed using FlowJo
software (Tristar, Palo Alto, CA, USA).
ELISA
Cytokines in serum and SF were assessed by ELISA. IL-10
was measured with antibody pairs from BD, IL-17-A and
IL-21 with antibody pairs from eBioscience (eBioscience
Inc, CA, USA). Blys/B cell activating factor (BAFF) was
measured using an ELISA kit from Biosupply (BioSupply
Ltd, UK).
Statistics
Statistical significance was calculated using the two-tailed
Student t test in the case of a Gaussian distribution (deter-
mined by the use of SPSS software, IBM); otherwise, the
Mann-Whitney test was used for unmatched groups and
the Wilcoxon test was used for paired groups. P values
<0.05 were regarded as statistically significant and are de-
noted as *p < 0.05, **p < 0.005 and ***p < 0.0005.
Results
Patients with inflammatory OA manifest qualitative and
quantitative differences in immune cell infiltrates in the
synovial compartment compared to patients with RA
To evaluate whether the immune cell compartments in
Patients with RA or OA differed from those in healthy
donors (HD), we first compared the frequencies and per-
formed statistical analysis of major circulating immune
cell subsets, i.e. B cells, CD4+ and CD8+ T cells, mono-
cytes and natural killer (NK) cells in PB. B cells were
more frequent in patients with OA and in those with
RA, whereas CD14+monocytes were selectively reduced
in patients with OA (Fig. 1a and b). Interestingly, al-
though total T-cell frequencies were largely unchanged,
patients with RA and those with OA had an increased
CD4:CD8 ratio (Fig. 1a, b).
We then analyzed infiltrating immune cells in the SF
(Fig. 1c, d) and in the SM (Additional file 1: Figure S1).
Immune cells were present in the SF and in the SM of
patients with RA and those with OA, as expected [7],
and the immune infiltrate was composed mostly of T
cells in both cases (Fig. 1c, d and Additional file 1: Figure
S1). However, the number of immune cells per milliliter in
SF from patients with OA was significantly lower than that
in patients with RA (104 vs 105/ml) (Table 1). Moreover,
patients with RA had a higher CD4:CD8 ratio in SF
(Fig. 1d).
CD4+ T cell subset frequencies in PB and in the synovial
compartment distinguish patients with RA from patients
with inflammatory OA
Next, we compared the frequencies of relevant CD4+ T
helper and regulatory subsets in PB and in SF from pa-
tients with RA and OA, identified according to well-
established phenotypic markers [11] (Fig. 2 and Additional
file 2: Figure S2).
Patients with RA had lower frequencies of circulating
CCR6+CXCR3−Th17, CCR6+CXCR3+Th1/17 [12] and of
CXCR5+ICOS+Tfh cells [13] as compared to patients
with OA (Fig. 2a), and the reduction in Th1/17 and
Th17 cells was statistically significant. Interestingly, pa-
tients with OA had significantly increased frequencies of
circulating Tr1 cells [15] as compared to both patients
with RA and HD, while frequencies of conventional
CD25+ Tregs were significantly reduced (Fig. 2b).
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Consistent with previous studies, we observed an im-
mune infiltrate of T helper cells in the synovial environ-
ment of patients with inflammatory OA [16] (Fig. 2c, d).
In the SF, patients with OA and patients with RA both
had high frequencies of Th1 cells and surprisingly, also of
Th1/17 cells, which are thought to play a prominent
pathogenic role in autoimmune arthritis [17] (Fig. 2c).
Conversely, patients with RA had higher frequencies of
Th17 [18, 19] and of Tfh cells than patients with OA
(Fig. 2c). However, the frequencies of Th17 cells were low
in a fraction of patients with RA, and therefore these
differences were not statistically significant (p = 0.0625).
Patients with RA had also higher frequencies of regulatory
T-cell subsets, and the increased frequency of conven-
tional CD25+ Treg cells was highly significant (Fig. 2d).
Notably, we observed very similar differences in the
Fig. 2 CD4+ T cell subset frequencies in blood and synovial fluid distinguish patients with rheumatoid arthritis (RA) from patients with
osteoarthritis (OA). Frequency of CD4+ T helper subsets (a, c) and T regulatory subsets (b, d) identified according to phenotypic markers in
blood and synovial fluid from healthy donors (HD) (open diamonds), patients with OA (open circles) and patients with RA (closed circles):
*p ≤ 0.05, **p ≤ 0.005, Mann-Whitney unpaired two-tailed t test. Mean value ± SEM are reported. Treg T regulatory cells, Th T helper cells
Fig. 1 Patients with osteoarthritis (OA) manifest qualitative and quantitative differences in the immune cell infiltrates in the synovial compartment
as compared to patients with rheumatoid arthritis (RA). Frequencies (a) and cumulative statistical analysis (b) of immune cell populations
(monocytes, CD14+, B cells CD19+, natural killer cells, CD56+, CD3+ CD4+ T cells and CD3+ CD8+ T cells) in peripheral blood (a, b) from healthy
donors (HD, n = 25) patients with OA (n = 11) and patients with RA (n = 24). Frequencies (c) and cumulative statistical analysis (d) of immune cell
populations in synovial fluid (SF) from patients with OA (n = 6) and patients with RA (n = 8): *p ≤ 0.05, **p≤ 0.005, ***p ≤ 0.0005, Mann-Whitney
unpaired two-tailed t test. Mean value ± SEM are reported. ns not significant, PBMC peripheral blood mononuclear cells, MC mononuclear cells
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synovial membranes (SM) collected from the subgroup
of patients who also underwent joint needle biopsy or
surgery for joint replacement (Additional file 3: Figure
S3A/B).
We then performed analysis of correlation between T
helper and regulatory subset frequencies in paired blood
and SF samples (Fig. 3). Interestingly, while no differ-
ences were observed in Th1 cells (Fig. 3a), in patients
with OA there was significant and strong enrichment of
Th1/17 cells in the SF (Fig. 3b), while conventional
Th17 cells were largely excluded (Fig. 3c). Conversely,
patients with RA did not have significant differences in
the frequencies of helper T-cell subsets in PB and SF, with
the notable exception of Tfh cells (Fig. 3a-d). Finally, we
compared the distribution of T regulatory subsets in blood
and SF from patients with RA and OA (Fig. 3e, f ). Patients
with RA had significantly increased frequencies of both
Tr1 (Fig. 3e) and Treg (Fig. 3f) subsets in SF as compared
to PB, whereas only Tr1 cells were significantly enriched
in SF from patients with OA (Fig. 3d). Notably, there were
no significant differences between SF and SM, consistent
with the view that T-cell subset distribution in the two
synovial compartments is similar (Additional file 3: Figure
S3C/D).
Cytokine levels in serum and SF differ in patients with
inflammatory OA and patients with RA, and correlate
with disease activity and ACPA positivity
Different T-cell subsets preferentially infiltrate the syno-
vium of patients with OA and RA. We asked if their
characteristic cytokine products in serum or SF might be
useful biomarkers to distinguish patients with RA from
patients with OA. We therefore analyzed the prototypical
cytokines that are produced by Th17 cells (IL-17, IL-21),
Tfh cells (Blys, IL-21) and by regulatory T-cell subsets (IL-
10). Notably, however, IL-10 was produced by both IL-7R-
and IL-7R+ T-cell subsets (Additional file 4: Figure S4),
which contain respectively mainly regulatory and helper T
cells [11, 15], suggesting that IL-10 is not exclusively de-
rived from regulatory T cells in patients with OA and pa-
tients with RA, in particular in the synovial compartment.
IL-17A (Fig. 4a), IL-10 (Fig. 4b) and Blys (Fig. 4c) serum
levels were significantly elevated in patients with RA but
not OA, as compared to HD. Moreover, IL-17A and in
particular Blys were also abundant in SF from patients
with RA (Fig. 4a and c) [20], but were hardly detectable in
patients with OA. In marked contrast, similar amounts of
IL-10 were present in SF from patients with RA and pa-
tients with OA (Fig. 4b). Interestingly, IL-21 was present
in serum from both patients with OA and those with RA,
but was completely absent in SF (Fig. 4d).
As cytokine levels in serum and SF differed between
patients with RA and OA, we asked if cytokine levels
could be useful also to distinguish patients with mild RA
from patients with inflammatory OA. Thus, we tested
correlation between the levels of cytokines in serum and
SF from patients with RA, and the DAS28 and anti-
citrullinated protein antibody (ACPA) positivity in these
patients and compared them to the levels measured in
serum and SF from patients with OA (Fig. 5).
Blys, a cytokine that induces differentiation and prolif-
eration of B cells and promotes the production of
Fig. 3 Tissue distribution of T-helper (Th) and T-regulatory (Treg) subsets in patients with rheumatoid arthritis (RA) and patients with osteoarthritis
(OA). Correlation between Th1 (a), Th1/17 (b), Th17 (c), Tfh (d), Tr1 (e) and Treg (f) subsets in paired samples of blood and synovial fluid (SF)
isolated from the same patients with OA and the same patients with RA on the same day (values from the same patients are connected by
lines): *p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.0005, Wilcoxon paired two-tailed t test
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autoantibodies [21], was elevated in patients with RA
who had a low DAS28, and, surprisingly, independent of
ACPA positivity, both in serum and in SF (Fig. 5a, b). In
marked contrast, serum IL-10 and IL17A was selectively
increased in patients with RA with ACPA (Fig. 5c, e),
and/or with an increased DAS28 (Fig. 5 d,f ), and there
was no significant association between the levels of these
cytokines and ACPA positivity or the DAS28 in the SF.
A statistically non-significant tendency was observed for
increased serum IL-21, ACPA positivity and DAS28
(Additional file 5: Figure S5). Of note, all patients posi-
tive for ACPA were also positive for rheumatoid factor
(RF) and there were no patients positive for RF only.
As expected, patients with OA had a higher mean age
than patients with RA, but on analysis of correlation
none of the analyzed parameters were significantly as-
sociated with age in the two patient groups (Additional
file 6: Figure S6 and Additional file 7: Figure S7). Moreover,
we also analyzed a possible impact of corticosteroid ther-
apy, but again found no significant association (Additional
file 8: Figure S8).
We concluded that levels of serum cytokine and Blys
in the SF could help to distinguish patients with RA
from those with OA. Most important, the levels of Blys
both in the serum and in the SF might distinguish pa-
tients with mild RA from patients with inflammatory
OA, whereas elevated serum IL-17A is a more selective
feature of severe and/or ACPA-positive patients with RA.
Discussion
Tissue-specific compartmentalization of immune cells is
a distinct pathogenic mechanism that accounts for the
selective accumulation of immune mediators in the
synovium of both patients with RA and patients with
OA. The striking differences in T-cell subset frequencies
that we observed in the analyzed patients underline the
pathogenic and clinical relevance of the analysis of tissues
from the affected joint during active effusion. Indeed, SF
samples directly reflect the inflammatory changes in the
synovial membrane, and are more easily accessible for re-
search and diagnostic purposes than needle biopsies.
To the best of our knowledge, this study is the first to
perform a comprehensive and simultaneous analysis of
both helper and regulatory T-cell subsets and their
functional products in PB and in the affected tissues of
patients with RA or OA. Consistent with previous stud-
ies, we observed an immune infiltrate in the synovium
of patients with inflammatory OA that contained many
Th1 cells [16]. Surprisingly, we also observed strong
enrichment of Th1/17 cells, which are thought to play
a prominent pathogenic role in autoimmune arthritis
[18] and also other organ-specific autoimmune diseases
[14]. However, the total cellularity in the SF was lower
than in patients with RA, and regulatory T cells were
quite frequent.
Consistent with the view that IL-10-producing Treg
and/or Tr1 cells control potentially pathogenic IL-17-
producing Th1/17 cells in the synovium of patients with
OA, IL-10 was quite abundant in SF, whereas IL-17A
was hardly detectable. Moreover, CD4+IL-7R− T cells,
which contain both Tr1 cells and Tregs [11, 15], produced
IL-10 in the synovium of patients with OA following poly-
clonal stimulation. Surprisingly however, we also observed
an increase in IL-10-producing IL-7R+CD4+ T cells, in
particular in the synovial compartment and in patients
with RA. Interestingly, as compared to patients with OA,
there are higher numbers of CCR6+IL-7R+TH17-cells
[18, 19] and CXCR5+ICOS+Tfh-cells in SF among many
but not all patients with RA. Importantly, both subsets
can produce IL-10, but provide help to B cells in the
production of IgG, and could play a pathogenic role in
autoantibody-driven autoimmune disease [22].
Of note, CD25+ Tregs and Tr1 cells were highly
enriched in SF and in the SM in patients with RA, but
were insufficient to control the local production of IL-
17A and Blys. We recently demonstrated that both
CD25+ Treg cells and Tr1 cells can regulate B-cell and
T-cell responses, and that Tr1-mediated suppression
of T-cell-dependent IgG production is selectively im-
paired in patients with systemic lupus erythematosus
Fig. 4 Cytokine levels in serum and synovial fluid discriminate
between patients with osteoarthritis (OA) and rheumatoid arthritis
(RA). Blys (a), IL-10 (b), IL-17A (c) and IL-21 (d) levels in serum from
healthy donors (HD) (n = 25), patients with OA (n = 11) and patients
with RA (n = 24) and in synovial fluid (SF) from patients with OA
(n = 10) and patients with RA (n = 8) patients: *p≤ 0.05, ** p≤ 0.005,
***p ≤ 0.0005, Mann-Whitney unpaired two-tailed t test. Mean
value ± SEM are reported. ns not significant
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[15]. It seems likely therefore that Tregs and/or Tr1
cells are also functionally impaired in the synovium of
patients with RA [23, 24]. In addition, we detected a
cytokine storm in serum from patients with RA who
had an elevated DAS28, suggesting that the function
of regulatory T cells in patients with severe RA is also
systemically compromised. Notably, however, while
cytokines such as IL-21 and IL-17 are predominantly
or exclusively produced by T cells, other cytokines
such as IL-10 and Blys are also secreted by myeloid
cells or B cells. Indeed, preliminary data suggests that
B cells in SF in patients with RA could spontaneously
secrete IL-10, indicating that B cells represent a relevant
source (data not shown). Blys induces differentiation
and proliferation of B cells and promotes the produc-
tion of autoantibodies [21]. We observed significant
increased levels of Blys both in serum and in SF from
patients with RA, and virtual absence of Blys in pa-
tients with OA. Most important, although Blys serum
and SF levels increased with disease activity in patients
with RA, Blys was also significantly increased in pa-
tients with RA who had a low DAS28, and the levels
of Blys were surprisingly independent of the presence
of ACPA or RF (data not shown). These findings, gen-
erated by the analysis in a cohort of patients with rela-
tively rare inflammatory OA, indicate that Blys might
be a useful biomarker to discriminate between mild
RA and inflammatory OA at the onset. These findings
might help to support the stratification of patients in
the future, and provide an additional tool to monitor
disease activity at diagnosis and upon subsequent
therapeutic interventions.
Fig. 5 Cytokine levels in serum and synovial fluid (SF) correlate with disease activity and anti-citrullinated protein antibody (ACPA) positivity. Correlation
between serum and synovial fluid levels of Blys (a, b), IL-17 (c, d) and IL-10 (e, f) in patients with rheumatoid arthritis (RA) stratified according to ACPA
positivity (a, c, e) or to the disease activity score in 28 joints (DAS28) (b, d, f), and cytokine levels in serum and synovial fluid from patients with
osteoarthritis (OA). Cytokine concentrations were determined by ELISA: *p≤ 0.05, **p≤ 0.005, ***p≤ 0.0005, two-tailed t test. Mean value ± SEM are
reported. ns not significant
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Conclusions
Although patients with inflammatory OA have immune
activation in the synovial compartment, they display a
specific immune signature, which is distinct from that in
patients with RA, and this is characterized by different
T-cell subset frequencies and cytokine profiles. In addition,
soluble mediators such as Blys might serve as biomarkers
to discriminate mild clinical forms of RA from inflamma-
tory OA at onset and during acute episodes.
Additional files
Additional file 1: Figure S1. Frequencies of immune cell populations
(monocytes CD14+, B cells CD19+, NK cells CD56+, CD3+ CD4+ T cells and
CD3+ CD8+ T cells) in the synovial membrane (SM) of patients with OA
(n = 9) and patients with RA (n = 4): *p≤ 0.05, unpaired two-tailed
Student t test. Mean value ± SEM are reported. (TIF 200 kb)
Additional file 2: Figure S2. Gating strategy to identify CD4+ T helper
and regulatory subsets. a Forward and side scatter indicating living
lymphocytes; b gate to identify CD4+ T cells; c CD127/CD25 gate to
identify memory (CD127+CD25−), effector (CD127−CD25−) and Treg cells
(CD127−CD25+); d among memory cells (CD127+CD25−), gates to identify
Th1 cells (CXCR3+CCR6−), Th1/17 cells (CXCR3+CCR6+) and Th17 cells
(CXCR3−CCR6+); e among memory cells (CD127+CD25−), gate to identify
Tfh cells (CXCR5+ICOS+); f Among effector cells (CD127−CD25−), gate to
identify Tr1 cells (CCR5+CCR6−). (TIF 5405 kb)
Additional file 3: Figure S3. Frequencies and statistical analysis of CD4
+ helper (a) and regulatory T cell subsets (b) among CD4+ lymphocytes
in the synovial membrane (SM) of patients with OA (n = 9) and patients
with RA (n = 4): *p ≤ 0.05, unpaired two-tailed Student t test. Mean value
± SEM are reported. c, d Comparison of the frequencies of helper and
regulatory T-cell subsets in synovial fluid and membranes in paired sam-
ples of the same patients with OA (lower panels) or RA (upper panels)
(values from the same patients are connected by lines). (TIF 2769 kb)
Additional file 4: Figure S4. Intracellular IL-10 staining among IL-7R–
(a) and IL7R+ (b) CD4+ T cells in the peripheral blood of healthy donors
(HD), in the peripheral blood of patients with OA or RA (OA Blood, RA
Blood), in the synovial fluid of patients with OA or RA (OA SF, RA SF) and
in the synovial membrane of patients with OA or RA (OA SM, RA SM)
following brief polyclonal activation with phorbole ester and calcium
ionophore. (TIF 443 kb)
Additional file 5: Figure S5. Correlation of serum levels of IL-21 between
patients with RA stratified according to positivity for autoantibodies (ACPA)
or to the DAS28 disease activity index compared to cytokines serum levels
in patients with OA. Cytokine concentrations were determined by ELISA.
Unpaired two-tailed Mann-Whitney test. Mean value ± SEM are reported.
(TIF 766 kb)
Additional file 6: Figure S6. Correlation between frequencies of CD4+
subsets significantly different between patients with RA and patients with
OA, and age of patients with RA. Frequency variations in Th17, Th1/17
and TFh CD4+ T helper subsets (a, b) and of Tr1 and CD25+ Treg
regulatory subsets (c, d) in peripheral blood (a, c) and synovial fluid (b, d)
in patients with RA and patients with OA are largely independent of
patient age. Pearson’s correlation coefficient: p > 0.05 for all. (TIF 439 kb)
Additional file 7: Figure S7. Serum (a) and synovial fluid (b) levels of
IL-10 (blue graphs), IL-17 (light blue graphs) and Blys (red graphs) in patients
with RA and patients with OA are largely independent of patient age.
Pearson’s correlation coefficient: p > 0.05 for all. (TIF 642 kb)
Additional file 8: Figure S8. Distribution of T helper (a, c) and T
regulatory (b, d) subsets in peripheral blood (upper panels) and synovial
fluid (lower panels) of significantly different subsets in patients with RA
according to CS therapy: statistical analysis by Mann-Whitney test, p > 0.05.
Peripheral blood: (a) Th1/17, Th17; (b) Tr1 and TReg subsets. Synovial fluid:
(c) Th1/17; (d) TReg subsets. (TIF 607 kb)
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